All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
11 - 20 of 102 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
Effect of zongertinib, a HER2-selective tyrosine kinase inhibitor, on the pharmacokinetics of midazolam and repaglinide in healthy male volunteers: an open-label, two-period, fixed-sequence trial
Author(s): Funck et al.
Zongertinib in HER2-altered breast cancer: preclinical activity and preliminary results from a Phase Ia dose-escalation study
Author(s): Berz et al.
Patient-reported outcomes evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): results from the Beamion™ LUNG-1 trial
Author(s): Sabari et al.
Beamion™ PANTUMOR-1: a Phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2-mutated or overexpressed/amplified solid tumors
Author(s): Schram et al.
An open-label, Phase Ib dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)–positive head and neck squamous cell carcinoma (HNSCC)
Author(s): Shroff et al.
DAREON®-9, a Phase Ib study of obrixtamig plus topotecan in patients with advanced small cell lung cancer (SCLC): interim analysis results
Author(s): Wermke et al.
Beamion™ BCGC-1: a Phase Ib/II dose escalation/optimization, randomized, open-label trial of oral zongertinib alone or in combination for advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)
Author(s): Hurvitz et al.
Absorption, distribution, metabolism, and excretion (ADME) properties and absolute bioavailability of zongertinib, a selective oral HER2-specific tyrosine kinase inhibitor, in healthy male subjects
Author(s): Joseph et al.
The effect of food on zongertinib plasma exposure in healthy volunteers
Author(s): Pereira et al.
An open-label, Phase Ib dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)-positive head and neck squamous cell carcinoma (HNSCC)
Author(s): Shroff et al.